{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:38:48Z","timestamp":1776087528922,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The aim of this systematic review and meta-analysis is to the summarize the evidence on programmed cell death protein ligand 1 (PD-L1) in Epstein-Barr virus associated gastric cancer (EBVaGC) and to estimate the expression rate of PD-L1 among this subtype of Gastric Cancer (GC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>For this study, PubMed<jats:sup>\u00ae<\/jats:sup>, EMBASE<jats:sup>\u00ae<\/jats:sup> and Web of Science<jats:sup>\u00ae<\/jats:sup> databases were searched for articles published until 1st November 2021. A total of 43 eligible publications with a total of 11,327 patients were included analysis based on inclusion and exclusion criteria. A total of 41 publications present data for proportion estimation and 33 for comparison of PD-L1 between EBV positive and negative GC. DerSimonian-Laird random-effects model was used for meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis showed that in EBVaGC the pooled positivity rate for PD-L1 was 54.6% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with a high heterogeneity between the included studies, which was associated with variation on positivity criteria for PD-L1 expression. Overall, the study reveals an increased association between PD-L1 and EBVaGC (OR\u2009=\u20096.36, 95% CI 3.91\u201310.3, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, the study revealed that GC with lymphoid stroma (GCLS) is highly associated with EBV (OR\u2009=\u200917.4, 95% CI 6.83\u201344.1, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with a pooled EBV positivity rate of 52.9% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with EBVaGC tend to show higher PD-L1 expression, which enhances EBV positivity as a promising marker for patient selection for immunotherapy targeted agents. A uniform criteria for PD-L1 positivity in tumor cells is needed, as well as further prospective studies to validate our findings and their prognostic significance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-022-00479-0","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T18:21:01Z","timestamp":1647973261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-0584","authenticated-orcid":false,"given":"\u00c1urea","family":"Lima","sequence":"first","affiliation":[]},{"given":"Hugo","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]},{"given":"Amanda","family":"Nobre","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Machado","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"issue":"3","key":"479_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7517","key":"479_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"6","key":"479_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cancers10060167","volume":"10","author":"J Nishikawa","year":"2018","unstructured":"Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, et al. Clinical Importance of Epstein (-) Barr Virus-Associated Gastric Cancer. Cancers. 2018;10(6):167.","journal-title":"Cancers"},{"issue":"3","key":"479_CR4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1053\/j.gastro.2009.05.001","volume":"137","author":"G Murphy","year":"2009","unstructured":"Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824\u201333.","journal-title":"Gastroenterology"},{"issue":"40","key":"479_CR5","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.3748\/wjg.v23.i40.7292","volume":"23","author":"J Ribeiro","year":"2017","unstructured":"Ribeiro J, Oliveira A, Malta M, Oliveira C, Silva F, Galaghar A, et al. Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal. World J Gastroenterol. 2017;23(40):7292\u2013302.","journal-title":"World J Gastroenterol"},{"issue":"27","key":"479_CR6","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3748\/wjg.14.4347","volume":"14","author":"H Sousa","year":"2008","unstructured":"Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance? World J Gastroenterol. 2008;14(27):4347\u201351.","journal-title":"World J Gastroenterol"},{"key":"479_CR7","doi-asserted-by":"publisher","unstructured":"de Sousa HML, Ribeiro JPC, Tim\u00f3teo MB. Epstein-Barr virus-associated gastric cancer: old entity with new relevance. In: Drouet E, editor. Epstein-Barr Virus: Intechopen; Norderstedt: BoD\u2013Books on Demand; 2021. https:\/\/doi.org\/10.5772\/intechopen.93649","DOI":"10.5772\/intechopen.93649"},{"issue":"5","key":"479_CR8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356.","journal-title":"Nat Med"},{"issue":"15","key":"479_CR9","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"BH Sohn","year":"2017","unstructured":"Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23(15):4441\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"479_CR10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000434683","volume":"82","author":"H Abe","year":"2015","unstructured":"Abe H, Kaneda A, Fukayama M. Epstein-Barr virus-associated gastric carcinoma: use of host cell machineries and somatic gene mutations. Pathobiology. 2015;82(5):212\u201323.","journal-title":"Pathobiology"},{"key":"479_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"479_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1349-7006.2007.00674.x","volume":"99","author":"S Akiba","year":"2008","unstructured":"Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 2008;99(2):195\u2013201.","journal-title":"Cancer Sci"},{"issue":"1","key":"479_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/bjc.2011.215","volume":"105","author":"MC Camargo","year":"2011","unstructured":"Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105(1):38\u201343.","journal-title":"Br J Cancer"},{"issue":"5","key":"479_CR14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/jcm9051427","volume":"9","author":"MG Rodriquenz","year":"2020","unstructured":"Rodriquenz MG, Roviello G, D\u2019Angelo A, Lavacchi D, Roviello F, Polom K. MSI and EBV positive gastric cancer\u2019s subgroups and their link with novel immunotherapy. J Clin Med. 2020;9(5):1427.","journal-title":"J Clin Med"},{"issue":"4","key":"479_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-015-0331-y","volume":"16","author":"Y Sunakawa","year":"2015","unstructured":"Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 2015;16(4):17.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"479_CR16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14740\/gr1187","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Liu G, Hu C. Molecular classification of gastric adenocarcinoma. Gastroenterol Res. 2019;12(6):275\u201382.","journal-title":"Gastroenterol Res"},{"key":"479_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2017.07.010","volume":"404","author":"J Ribeiro","year":"2017","unstructured":"Ribeiro J, Malta M, Galaghar A, Silva F, Afonso LP, Medeiros R, et al. P53 deregulation in Epstein-Barr virus-associated gastric cancer. Cancer Lett. 2017;404:37\u201343.","journal-title":"Cancer Lett"},{"issue":"21","key":"479_CR18","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.3748\/wjg.v20.i21.6448","volume":"20","author":"TO Yau","year":"2014","unstructured":"Yau TO, Tang CM, Yu J. Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments. World J Gastroenterol. 2014;20(21):6448\u201356.","journal-title":"World J Gastroenterol"},{"issue":"22","key":"479_CR19","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332.","journal-title":"Oncotarget"},{"issue":"10","key":"479_CR20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.cgh.2015.04.015","volume":"13","author":"H Lim","year":"2015","unstructured":"Lim H, Park YS, Lee JH, Son DH, Ahn JY, Choi KS, et al. Features of gastric carcinoma with lymphoid stroma associated with epstein-barr virus. Clin Gastroenterol Hepatol. 2015;13(10):1738-44.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"479_CR21","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/1097-0142(19940501)73:9<2239::AID-CNCR2820730902>3.0.CO;2-#","volume":"73","author":"S Nakamura","year":"1994","unstructured":"Nakamura S, Ueki T, Yao T, Ueyama T, Tsuneyoshi M. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer. 1994;73(9):2239\u201349.","journal-title":"Cancer"},{"issue":"6","key":"479_CR22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10120-020-01095-z","volume":"23","author":"E Ignatova","year":"2020","unstructured":"Ignatova E, Seriak D, Fedyanin M, Tryakin A, Pokataev I, Menshikova S, et al. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020;23(6):951\u201360.","journal-title":"Gastric Cancer"},{"issue":"3","key":"479_CR23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/den.13584","volume":"32","author":"H Osumi","year":"2020","unstructured":"Osumi H, Kawachi H, Yoshio T, Fujisaki J. Clinical impact of Epstein-Barr virus status on the incidence of lymph node metastasis in early gastric cancer. Dig Endosc. 2020;32(3):316\u201322.","journal-title":"Dig Endosc"},{"key":"479_CR24","doi-asserted-by":"crossref","first-page":"583463","DOI":"10.3389\/fonc.2020.583463","volume":"10","author":"K Sun","year":"2020","unstructured":"Sun K, Jia K, Lv H, Wang SQ, Wu Y, Lei H, et al. EBV-positive gastric cancer: current knowledge and future perspectives. Front Oncol. 2020;10:583463.","journal-title":"Front Oncol"},{"key":"479_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett. 2020;495:191\u20139.","journal-title":"Cancer Lett"},{"issue":"6165","key":"479_CR26","first-page":"1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunother Sci. 2013;342(6165):1432\u20133.","journal-title":"Cancer Immunother Sci"},{"key":"479_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine J, Taube JM. PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32\u20138.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"479_CR28","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"key":"479_CR29","unstructured":"FDA. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017. https:\/\/www.fda.gov\/drus\/informationondrugs\/approveddrugs\/ucm560040.htm."},{"issue":"6","key":"479_CR30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326.","journal-title":"Lancet Oncol"},{"issue":"5","key":"479_CR31","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"8","key":"479_CR32","doi-asserted-by":"crossref","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS ONE. 2017;12(8):e0182692.","journal-title":"PLoS ONE"},{"issue":"9","key":"479_CR33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"6","key":"479_CR34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/fon-2018-0668","volume":"15","author":"M Moehler","year":"2019","unstructured":"Moehler M, Ryu MH, Dvorkin M, Lee KW, Coskun HS, Wong R, et al. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncol. 2019;15(6):567\u201377.","journal-title":"Future Oncol"},{"issue":"3","key":"479_CR35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnci\/djx213","volume":"110","author":"A Panda","year":"2018","unstructured":"Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, et al. Immune activation and benefit from avelumab in EBV-positive gastric cancer. J Natl Cancer Inst. 2018;110(3):316\u201320.","journal-title":"J Natl Cancer Inst"},{"key":"479_CR36","doi-asserted-by":"crossref","unstructured":"Young RS, Lee JB, Kim HS, Jung M, Lee C-k, Park SR, et al. Abstract CT159: Open label, single-arm, multi-center phase Ib\/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC). Cancer Res. 2021;81(13 Suppl).","DOI":"10.1158\/1538-7445.AM2021-CT159"},{"issue":"1","key":"479_CR37","first-page":"1","volume":"2","author":"GA Wells","year":"1999","unstructured":"Wells GA, Sboc D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa (NOS) scale for assessing the quality of nonrandomised studies in meta analyses. Ott Health Res Inst. 1999;2(1):1\u20132.","journal-title":"Ott Health Res Inst"},{"key":"479_CR38","unstructured":"The jamovi project. jamovi (version 1.6) [Computer Software]. 2021. Retrieved from https:\/\/www.jamovi.org."},{"key":"479_CR39","unstructured":"R Core Team. R: A Language and environment for statistical computing. (Version 4.0). 2020. Retrieved from https:\/\/cran.r-project.org."},{"issue":"3","key":"479_CR40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):48.","journal-title":"J Stat Softw"},{"issue":"13","key":"479_CR41","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/cancers13133107","volume":"13","author":"CFA Moreira-Nunes","year":"2021","unstructured":"Moreira-Nunes CFA, Martins C, Feio D, Lima IK, Lamar\u00e3o LM, de Souza CRT, et al. Pd-l1 expression associated with epstein\u2014barr virus status and patients\u2019 survival in a large cohort of gastric cancer patients in northern brazil. Cancers. 2021;13(13):3107.","journal-title":"Cancers"},{"key":"479_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9980410","author":"JP Nshizirungu","year":"2021","unstructured":"Nshizirungu JP, Bennis S, Mellouki I, Sekal M, Benajah DA, Lahmidani N, et al. Reproduction of the cancer genome atlas (TCGA) and Asian cancer research group (ACRG) gastric cancer molecular classifications and their association with clinicopathological characteristics and overall survival in moroccan patients. Dis Mark. 2021. https:\/\/doi.org\/10.1155\/2021\/9980410.","journal-title":"Dis Mark"},{"key":"479_CR43","doi-asserted-by":"crossref","first-page":"e11481","DOI":"10.7717\/peerj.11481","volume":"9","author":"N Yang","year":"2021","unstructured":"Yang N, Wu Y, Jin M, Jia Z, Wang Y, Cao D, et al. Microsatellite instability and epstein-barr virus combined with pd-l1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer. PeerJ. 2021;9:e11481.","journal-title":"PeerJ"},{"issue":"1","key":"479_CR44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13000-020-00979-z","volume":"15","author":"E Choi","year":"2020","unstructured":"Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, et al. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn Pathol. 2020;15(1):69.","journal-title":"Diagn Pathol"},{"issue":"8","key":"479_CR45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1159\/000506077","volume":"98","author":"F Di Pinto","year":"2020","unstructured":"Di Pinto F, Armentano R, Arborea G, Schena N, Donghia R, Valentini AM. Are immunohistochemical markers useful in phenotypic gastric cancer classification? Oncology. 2020;98(8):566\u201374.","journal-title":"Oncology"},{"issue":"6","key":"479_CR46","first-page":"1","volume":"12","author":"WL Fang","year":"2020","unstructured":"Fang WL, Chen MH, Huang KH, Lin CH, Chao Y, Lo SS, et al. The clinicopathological features and genetic alterations in epstein\u2013barr virus-associated gastric cancer patients after curative surgery. Cancers. 2020;12(6):1\u201317.","journal-title":"Cancers"},{"issue":"6","key":"479_CR47","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.21873\/invivo.12152","volume":"34","author":"D Hyun Kim","year":"2020","unstructured":"Hyun Kim D, Bae GE, Suh KS, Ryuman D, Song KS, Kim JS, et al. Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma. In Vivo. 2020;34(6):3171\u201380.","journal-title":"In Vivo"},{"issue":"4","key":"479_CR48","doi-asserted-by":"crossref","first-page":"152881","DOI":"10.1016\/j.prp.2020.152881","volume":"216","author":"X Liu","year":"2020","unstructured":"Liu X, Choi MG, Kim K, Kim KM, Kim ST, Park SH, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216(4):152881.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"479_CR49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cancers12010198","volume":"12","author":"HA Martinson","year":"2020","unstructured":"Martinson HA, Mallari D, Richter C, Wu TT, Tiesinga J, Alberts SR, et al. Molecular classification of gastric cancer among alaska native people. Cancers. 2020;12(1):198.","journal-title":"Cancers"},{"issue":"4","key":"479_CR50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CJI.0000000000000316","volume":"43","author":"T Xie","year":"2020","unstructured":"Xie T, Liu YQ, Zhang ZN, Zhang XT, Gong JF, Qi CS, et al. Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother. 2020;43(4):139\u201344.","journal-title":"J Immunother"},{"issue":"1","key":"479_CR51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10120-018-0836-8","volume":"22","author":"I Gullo","year":"2019","unstructured":"Gullo I, Oliveira P, Athelogou M, Gon\u00e7alves G, Pinto ML, Carvalho J, et al. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer. 2019;22(1):77\u201390.","journal-title":"Gastric Cancer"},{"issue":"1","key":"479_CR52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10120-018-0843-9","volume":"22","author":"A Kawazoe","year":"2019","unstructured":"Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, et al. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer. 2019;22(1):69\u201376.","journal-title":"Gastric Cancer"},{"issue":"4","key":"479_CR53","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.32140","volume":"145","author":"YB Kim","year":"2019","unstructured":"Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916\u201326.","journal-title":"Int J Cancer"},{"issue":"6","key":"479_CR54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s10120-019-00974-4","volume":"22","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kim WG, Kwon CH, Park DY. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer. 2019;22(6):1164\u201375.","journal-title":"Gastric Cancer"},{"issue":"1","key":"479_CR55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7(1):24.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"479_CR56","first-page":"1358","volume":"14","author":"A Nakayama","year":"2019","unstructured":"Nakayama A, Abe H, Kunita A, Saito R, Kanda T, Yamashita H, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr virus-associated gastric carcinoma. PLoS ONE. 2019;14(1):1358.","journal-title":"PLoS ONE"},{"key":"479_CR57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.humpath.2019.10.008","volume":"94","author":"N Setia","year":"2019","unstructured":"Setia N, Ahn S, Han HS, Park DY, Lauwers GY. Predictive value of WHO classification for PD-L1 and Her2\/Neu expression and distinct associations with protein expression based classification in gastric carcinoma. Hum Pathol. 2019;94:64\u201370.","journal-title":"Hum Pathol"},{"key":"479_CR58","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.2147\/CMAR.S206189","volume":"11","author":"Y Sun","year":"2019","unstructured":"Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, et al. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag Res. 2019;11:6397\u2013410.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"479_CR59","first-page":"1775","volume":"18","author":"AM Valentini","year":"2019","unstructured":"Valentini AM, Di Pinto F, Coletta S, Guerra V, Armentano R, Caruso ML. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol Lett. 2019;18(2):1775\u201385.","journal-title":"Oncol Lett"},{"issue":"12","key":"479_CR60","doi-asserted-by":"crossref","first-page":"e0224812","DOI":"10.1371\/journal.pone.0224812","volume":"14","author":"JY Yoon","year":"2019","unstructured":"Yoon JY, Sy K, Brezden-Masley C, Streutker CJ. Histo- And immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: a single-institution study. PLoS ONE. 2019;14(12):e0224812.","journal-title":"PLoS ONE"},{"issue":"1","key":"479_CR61","doi-asserted-by":"crossref","first-page":"13887","DOI":"10.1038\/s41598-018-32299-0","volume":"8","author":"YH Chang","year":"2018","unstructured":"Chang YH, Heo YJ, Cho J, Song SY, Lee J, Kim KM. Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. Sci Rep. 2018;8(1):13887.","journal-title":"Sci Rep"},{"issue":"6","key":"479_CR62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10120-018-0820-3","volume":"21","author":"CJ Cho","year":"2018","unstructured":"Cho CJ, Kang HJ, Ryu YM, Park YS, Jeong HJ, Park YM, et al. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer. 2018;21(6):925\u201335.","journal-title":"Gastric Cancer"},{"issue":"4","key":"479_CR63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/cancers10040102","volume":"10","author":"S de Rosa","year":"2018","unstructured":"de Rosa S, Sahnane N, Tibiletti MG, Magnoli F, Vanoli A, Sessa F, et al. EBV+ and MSI gastric cancers harbor high PD-L1\/PD-1 expression and high CD8+ intratumoral lymphocytes. Cancers. 2018;10(4):102.","journal-title":"Cancers"},{"issue":"7","key":"479_CR64","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3390\/ijms19072079","volume":"19","author":"I Gullo","year":"2018","unstructured":"Gullo I, Carvalho J, Martins D, Lemos D, Monteiro AR, Ferreira M, et al. The transcriptomic landscape of gastric cancer: insights into epstein-barr virus infected and microsatellite unstable tumors. Int J Mol Sci. 2018;19(7):2079.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"479_CR65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAS.0000000000001018","volume":"42","author":"E Hissong","year":"2018","unstructured":"Hissong E, Ramrattan G, Zhang P, Zhou XK, Young G, Klimstra DS, et al. Gastric carcinomas with lymphoid stroma: an evaluation of the histopathologic and molecular features. Am J Surg Pathol. 2018;42(4):453\u201362.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"479_CR66","first-page":"695","volume":"48","author":"BJ Noh","year":"2018","unstructured":"Noh BJ, Kim JH, Eom DW. Prognostic significance of categorizing gastric carcinoma by PD-L1 expression and tumor infiltrating lymphocytes. Ann Clin Lab Sci. 2018;48(6):695\u2013706.","journal-title":"Ann Clin Lab Sci"},{"issue":"5","key":"479_CR67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jso.25022","volume":"117","author":"MA Pereira","year":"2018","unstructured":"Pereira MA, Ramos M, Faraj SF, Dias AR, Yagi OK, Zilberstein B, et al. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol. 2018;117(5):829\u201339.","journal-title":"J Surg Oncol"},{"issue":"6","key":"479_CR68","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s10120-018-0851-9","volume":"21","author":"R Sundar","year":"2018","unstructured":"Sundar R, Qamra A, Tan ALK, Zhang S, Ng CCY, Teh BT, et al. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer. 2018;21(6):1064\u201370.","journal-title":"Gastric Cancer"},{"issue":"3","key":"479_CR69","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407\u201315.","journal-title":"Gastric Cancer"},{"issue":"16","key":"479_CR70","doi-asserted-by":"crossref","first-page":"26356","DOI":"10.18632\/oncotarget.15465","volume":"8","author":"J Koh","year":"2017","unstructured":"Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, et al. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget. 2017;8(16):26356\u201367.","journal-title":"Oncotarget"},{"issue":"47","key":"479_CR71","doi-asserted-by":"crossref","first-page":"82399","DOI":"10.18632\/oncotarget.19390","volume":"8","author":"MJ Kwon","year":"2017","unstructured":"Kwon MJ, Kim KC, Nam ES, Cho SJ, Park HR, Min SK, et al. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget. 2017;8(47):82399\u2013414.","journal-title":"Oncotarget"},{"issue":"40","key":"479_CR72","doi-asserted-by":"crossref","first-page":"67094","DOI":"10.18632\/oncotarget.17945","volume":"8","author":"J Ma","year":"2017","unstructured":"Ma J, Li J, Hao Y, Nie Y, Li Z, Qian M, et al. Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. Oncotarget. 2017;8(40):67094\u2013103.","journal-title":"Oncotarget"},{"issue":"3","key":"479_CR73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","volume":"30","author":"R Saito","year":"2017","unstructured":"Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol. 2017;30(3):427\u201339.","journal-title":"Mod Pathol"},{"issue":"12","key":"479_CR74","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/bjc.2017.369","volume":"117","author":"AN Seo","year":"2017","unstructured":"Seo AN, Kang BW, Kwon OK, Park KB, Lee SS, Chung HY, et al. Intratumoural PD-l1 expression is associated with worse survival of patients with epstein\u2013barr virus-associated gastric cancer. Br J Cancer. 2017;117(12):1753\u201360.","journal-title":"Br J Cancer"},{"issue":"5","key":"479_CR75","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794\u2013801.","journal-title":"Gut"},{"issue":"38","key":"479_CR76","doi-asserted-by":"crossref","first-page":"64066","DOI":"10.18632\/oncotarget.19318","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8(38):64066\u201382.","journal-title":"Oncotarget"},{"issue":"17","key":"479_CR77","doi-asserted-by":"crossref","first-page":"24269","DOI":"10.18632\/oncotarget.8169","volume":"7","author":"C B\u00f6ger","year":"2016","unstructured":"B\u00f6ger C, Behrens HM, Mathiak M, Kr\u00fcger S, Kalthoff H, R\u00f6cken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7(17):24269\u201383.","journal-title":"Oncotarget"},{"issue":"10","key":"479_CR78","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.molonc.2016.09.004","volume":"10","author":"C Dai","year":"2016","unstructured":"Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, et al. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10(10):1551\u20138.","journal-title":"Mol Oncol"},{"key":"479_CR79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.humpath.2016.02.007","volume":"53","author":"M Dong","year":"2016","unstructured":"Dong M, Wang HY, Zhao XX, Chen JN, Zhang YW, Huang Y, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol. 2016;53:25\u201334.","journal-title":"Hum Pathol"},{"issue":"11","key":"479_CR80","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1245\/s10434-016-5284-2","volume":"23","author":"HJ Kang","year":"2016","unstructured":"Kang HJ, Lee IS, Park YS, Ho WJ, Sohn D, Ahn JY, et al. Biomarkers of EBV-positive gastric cancers: loss of PTEN expression is associated with poor prognosis and nodal metastasis. Ann Surg Oncol. 2016;23(11):3684\u201392.","journal-title":"Ann Surg Oncol"},{"key":"479_CR81","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.humpath.2016.05.012","volume":"55","author":"Z Li","year":"2016","unstructured":"Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 2016;55:182\u20139.","journal-title":"Hum Pathol"},{"issue":"11","key":"479_CR82","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, et al. Programmed death-Ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am J Surg Pathol. 2016;40(11):1496\u2013506.","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"479_CR83","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"479_CR84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"issue":"19","key":"479_CR85","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"10212","key":"479_CR86","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"4","key":"479_CR87","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421\u201334.","journal-title":"Int J Oncol"},{"issue":"10","key":"479_CR88","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<1998::AID-CNCR6>3.0.CO;2-D","volume":"77","author":"H Matsunou","year":"1996","unstructured":"Matsunou H, Konishi F, Hori H, Ikeda T, Sasaki K, Hirose Y, et al. Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer. 1996;77(10):1998\u20132004.","journal-title":"Cancer"},{"issue":"12","key":"479_CR89","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/COC.0000000000000449","volume":"41","author":"N Larbcharoensub","year":"2018","unstructured":"Larbcharoensub N, Mahaprom K, Jiarpinitnun C, Trachu N, Tubthong N, Pattaranutaporn P, et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma. Am J Clin Oncol. 2018;41(12):1204\u201310.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"479_CR90","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jcp.47.6.538","volume":"47","author":"K Horiuchi","year":"1994","unstructured":"Horiuchi K, Mishima K, Ohsawa M, Aozasa K. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus. J Clin Pathol. 1994;47(6):538\u201340.","journal-title":"J Clin Pathol"},{"issue":"1","key":"479_CR91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.gastro.2010.04.002","volume":"139","author":"HJ Song","year":"2010","unstructured":"Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Ki Kang W, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology. 2010;139(1):84-92.e2.","journal-title":"Gastroenterology"},{"issue":"1","key":"479_CR92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12957-020-01878-9","volume":"18","author":"K Iwasaki","year":"2020","unstructured":"Iwasaki K, Suda T, Takano Y, Ohno Y, Yamada E, Okazaki N, et al. Postoperative outcomes of gastric carcinoma with lymphoid stroma. World J Surg Oncol. 2020;18(1):102.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"479_CR93","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4","volume":"38","author":"H Watanabe","year":"1976","unstructured":"Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma Its morphologic characteristics and prognostic correlations. Cancer. 1976;38(1):232\u201343.","journal-title":"Cancer"},{"issue":"10","key":"479_CR94","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1007\/s00464-017-5470-8","volume":"31","author":"DH Shin","year":"2017","unstructured":"Shin DH, Kim GH, Lee BE, Lee JW, Ha DW, Jeon HK, et al. Clinicopathologic features of early gastric carcinoma with lymphoid stroma and feasibility of endoscopic submucosal dissection. Surg Endosc. 2017;31(10):4156\u201364.","journal-title":"Surg Endosc"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00479-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-022-00479-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-022-00479-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T18:22:02Z","timestamp":1647973322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-022-00479-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s12672-022-00479-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}